Podium Session 2: Urologic Malignancies

Treatment of bone metastases in urologic malignancies.

The skeletal system is the most common site of metastatic cancer spread. Bone metastases are often associated with severe morbidity, pain and functional impairment. Timely diagnosis and proper treatment may decrease morbidity, improve quality of life and in some cases even improve survival. External beam radiotherapy may effectively give pain relief in patients with painful bone metastases. In ...

Extracellular MicroRNAs in Urologic Malignancies: Chances and Challenges

Small noncoding RNAs that are 19-23 nucleotides long, known as microRNAs (miRNAs), are involved in almost all biological mechanisms during carcinogenesis. Recent studies show that miRNAs released from live cells are detectable in body fluids and may be taken up by other cells to confer cell-cell communication. These released miRNAs (here referred to as extracellular miRNAs) are often protected ...

Podium for the opposition?

This is quite a paradoxical era. Scientific research is in its most productive phase and it continues to produce many beneficial technologies for mankind. For example, we rapidly progress towards a better understanding of many diseases and come up with multiple new approaches to cure them. At the same time, however, the voices against science and technology have never been more shrill. But unsu...

Session 2

Long Non-coding RNAs in Urologic Malignancies: Functional Roles and Clinical Translation

Early diagnosis and surveillance for metastasis and recurrences are critical issues of urologic cancer. Deregulation of long non-coding RNAs (lncRNAs) has been implicated in urologic malignancies and represents potential markers or therapeutic targets. However, the utility of lncRNA as biomarkers appears to be overstated due to heterogeneous or irreproducible results from different studies. Thu...